Surrozen, Inc.
NASDAQ:SRZNBiotechnology
-$1.14 today
- Market cap
- $237.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
Volume 0.31M
Average 0.11M
SRZN Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Surrozen, Inc.NASDAQ: SRZN
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $30.28M fell 60.4% year over year, behind the -57.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 119.7% from the prior quarter.
Context
- Financing cash flow amounted to 2446.1% of revenue in FY2025, up 2294.3 pp from a year earlier.
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -60.4% toward the trailing-twelve-month pace of -57.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 85.05M USD
- Year-over-year change
- +425.8%
- 4-year CAGR
- -9.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 85.05M | +425.8% |
| FY2024 | 2024-12-31 | 16.18M | +5760.9% |
| FY2023 | 2023-12-31 | 276K | +110.8% |
| FY2022 | 2022-12-31 | (2.57M) | -102.1% |
| FY2021 | 2021-12-31 | 124.63M | — |
Financing Cash Flow vs competitors
How SRZN compares with its peers on the latest reported figures
- SRZN's LTM Mar 2026 financing cash flow of $38.95M is the 3rd largest of the 8 companies compared; the peer median is $32.01M.
- Its year-over-year change of -57.9% is the 6th highest of 7, against a peer median of +164.4%.
- Financing cash flow amounts to 519.7% of revenue for SRZN, versus a peer median of 77.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $107.35M | — | +221.5% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $57.15M | +156.6% | +136.4% | 477.0% |
| LTM Mar 2026 | $38.95M | -57.9% | — | 519.7% | |
| LTM Mar 2026 | $35.04M | +172.3% | +87.5% | — | |
| LTM Mar 2026 | $32.01M | -71.3% | +8.6% | 25.8% | |
| LTM Mar 2026 | $20.54M | +350.1% | — | — | |
| LTM Mar 2026 | $11.67M | -10.2% | — | 77.6% | |
| LTM Mar 2026 | $7.06M | +255.3% | -53.4% | — | |
| Peer median (excluding SRZN) | $32.01M | +164.4% | +87.5% | 77.6% | |
Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (54.65M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Depreciation & Amortization | 2.07M | 1.96M | 1.91M | 1.44M | 537K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.32M | 4.52M | 4.37M | 4.11M | 3.84M |
| Change in Working Capital | (221K) | (8.42M) | (3.93M) | (836K) | 3.15M |
| Accounts Receivables | 0 | (1.98M) | 0 | (502K) | 2.33M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 857K | (2.04M) | (133K) | (228K) | 142K |
| Other Working Capital | (1.08M) | (4.4M) | (3.8M) | (106K) | 678K |
| Other Non-Cash Items | 1.67M | (6.2M) | 325K | 41.22M | 204.26M |
| Operating Cash Flow | (48.81M) | (44.15M) | (40.36M) | (17.63M) | (30.24M) |
| Capital Expenditures | (1.27M) | (728K) | (398K) | (26K) | (128K) |
| Acquisitions (Net) | 0 | (39.04M) | 0 | 0 | 0 |
| Purchases of Investments | (91.74M) | (29.6M) | (28.04M) | 0 | 0 |
| Sales of Investments | 15.3M | 68.64M | 80.17M | 0 | 0 |
| Other Investing Activities | 0 | 39.04M | 0 | 0 | 0 |
| Investing Cash Flow | (77.71M) | 38.31M | 51.72M | (26K) | (128K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 124.22M | 42K | 280K | 16.04M | 85.05M |
| Common Stock Repurchased | 0 | (2.61M) | (4K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 410K | (85K) | 280K | 133K | 0 |
| Financing Cash Flow | 124.63M | (2.57M) | 276K | 16.18M | 85.05M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.89M) | (8.4M) | 11.64M | (1.48M) | 54.68M |
| Free Cash Flow | (50.08M) | (44.87M) | (40.76M) | (17.65M) | (30.37M) |
Surrozen, Inc.
NASDAQ:SRZN
Intrinsic Alpha fair value
Locked
Current Price
$31.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.